Interim EARLY TAVR Data Reaffirms Role of Intervention in Asymptomatic Cohort

Research evidence excerpt

Interim EARLY TAVR Data Reaffirms Role of Intervention in Asymptomatic Cohort

Medical Supplies & Devices: Cardiovascular

Edwards Lifesciences Corp.

TD SECURITIES (USA) LLC COMPANY UPDATE

June 29, 2026

Price: $90.78 (06/26/2026) Interim EARLY TAVR Data Reaffirms Role of

Price Target: $104.00 Intervention in Asymptomatic Cohort

BUY (1)

Joshua Jennings, M.D. THE TD COWEN INSIGHT

646 562 1333

Last week at NY Valves, investigators presented interim data for the EARLY TAVR Trial. Five-

joshua.jennings@tdsecurities.com

year data, for which ~97% of the study pop. was eligible, reconfirmed the superiority of early

John Rusch, CFA intervention with TAVR compared to clinical surveillance (CS), with respect to the composite

646 562 1324 endpoint of death, stroke, or (HF) hospitalization. Reiterate Buy, and we look for 2H26 updates

john.rusch@tdsecurities.com

to the pending TAVR NCD.

Colin Clark

646 562 1441 Last week at NY Valves, investigators presented interim data for the EARLY TAVR Trial. Using

colin.clark@tdsecurities.com interim five-year data, for which ~97% of the patient population was eligible, results confirmed

Key Data the superiority of early intervention with TAVR compared to clinical surveillance (CS) with

Symbol NYSE: EW respect to the composite endpoint of death, stroke, or heart failure (HF) hospitalization.

Beta: 0.87 Furthermore, presenters noted that, in the first two years, early TAVR was associated with a

52-Week Range: $90.78-$72.65 reduction in rates of HF hospitalization, with no treatment penalty seen for death or stroke.

Following two years, the continued benefit of TAVR was demonstrated by lower rates of death

Market Cap: $52.3B

and stroke. We agree with investigators' conclusions that the data presented reaffirms the

Net Debt (MM): $(2,969.6)